SFE Investment Counsel Invests $2.67 Million in Becton, Dickinson and Company $BDX

SFE Investment Counsel acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 17,614 shares of the medical instruments supplier’s stock, valued at approximately $2,666,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Everett Harris & Co. CA purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $84,132,000. Oppenheimer Asset Management Inc. purchased a new stake in Becton, Dickinson and Company in the second quarter valued at $13,739,000. Bryn Mawr Trust Advisors LLC acquired a new position in Becton, Dickinson and Company in the second quarter valued at $7,011,000. Mill Capital Management LLC purchased a new position in shares of Becton, Dickinson and Company during the second quarter worth about $522,000. Finally, Northstar Group Inc. acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $240,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. TD Cowen boosted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $183.16 on Friday. The stock’s 50 day moving average is $157.84 and its two-hundred day moving average is $161.70. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The firm has a market capitalization of $50.47 billion, a PE ratio of 55.17, a P/E/G ratio of 12.93 and a beta of 0.19. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the business posted $3.68 earnings per share. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the transaction, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 11,779 shares of company stock valued at $1,974,669. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.